Zeng P, Xiao J, Lei Y
Third Affiliated Hospital, Hunan Medical University, Changsha.
Zhonghua Zhong Liu Za Zhi. 1995 May;17(3):223-5.
Cimetidine (CMD), an H2 receptor antagonist, was used in combination with radiation for the treatment of patirnts with nasopharyngeal cancer (NPC). In patients treated with radiotherapy alone, there was an increase in the number of CD4+ T cells and in NK cell activity. In patients received combined treatment of radiation and CMD, in addition, there was a decrease in CD8+ T cells with an increase in CD4/CD8 ratio and an increase in IL-2 production. The NK cell activity was also stronger in the latter group. The results suggest that CMD helps restore cell-mediated immunity in NPC patients radiation treated.
西咪替丁(CMD)是一种H2受体拮抗剂,与放疗联合用于治疗鼻咽癌(NPC)患者。在仅接受放疗的患者中,CD4 + T细胞数量和NK细胞活性增加。此外,在接受放疗和CMD联合治疗的患者中,CD8 + T细胞减少,CD4/CD8比值增加,IL-2产生增加。后一组的NK细胞活性也更强。结果表明,CMD有助于恢复接受放疗的NPC患者的细胞介导免疫。